Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Blinatumomab

Drug (Brand/Generic)

Blinatumomab / MT103

Company / Licensee

Micromet

Therapy Class

Monoclonal antibody

Product Description

Lymphoma-directed, recombinant bispecific single-chain antibody

Current Indication

Non-Hodgkin's lymphoma and acute lymphoblastic leukaemia, lung or gastrointestinal cancers

Market Sector

Oncology

Development Status

Phase I (non-Hodgkin's lymphoma); Phase II (acute lymphoblastic leukaemia)
Expand

Go Top